托珠单抗诱发的新冠病毒病患者巨细胞病毒性结肠炎

Tocilizumab-induced cytomegalovirus colitis in a patient with COVID-19.

作者信息

Khatib Mohamad Y, Shaik Karimulla S, Ahmed Amna A, Alwraidat Mohammad A, Mohamed Ahmed S, Abou Kamar Mohamad R, Sharaf Eldean Mouhammad Z, Aldaraiseh Bashar K, Nashwan Abdulqadir J

机构信息

Critical Care Unit Hazm Mebaireek General Hospital (HMGH) Hamad Medical Corporation (HMC) Doha Qatar.

Department of Infectious Diseases Communicable Disease Center (CDC) Hamad Medical Corporation (HMC) Doha Qatar.

出版信息

Clin Case Rep. 2020 Nov 12;9(1):148-152. doi: 10.1002/ccr3.3487. eCollection 2021 Jan.

The authors urge clinicians to observe for early signs of CMV reactivation in patients presenting with gastrointestinal bleeding and intestinal perforation after receiving tocilizumab or other immunosuppressive therapy as a treatment for COVID 19. Early recognition of CMV infection and treatment will prevent life-threatening bleeding and mortality.